Pulmonary hypertension (PH) is a condition characterized by elevated pulmonary arterial pressure and secondary right ventricular failure. It is a progressive disorder with a high morbidity and mortality rate, necessitating a comprehensive understanding for effective management.
PH affects individuals of all ages, with a higher prevalence in females. The pathophysiology of PH is complex and multifactorial, involving endothelial dysfunction, vasoconstriction, and vascular remodeling. These changes lead to increased pulmonary vascular resistance, ultimately resulting in right ventricular overload and failure.
PH often presents insidiously, with nonspecific symptoms such as dyspnea, fatigue, and syncope. As the disease progresses, patients may develop signs of right heart failure, including peripheral edema and ascites. The diagnosis is often delayed due to the nonspecific nature of these symptoms.
The diagnostic approach to PH involves a combination of clinical evaluation, echocardiography, and right heart catheterization. Echocardiography is often the initial test of choice, providing an estimate of pulmonary artery pressure and assessing right ventricular function. Right heart catheterization, however, remains the gold standard for diagnosis, allowing for direct measurement of pulmonary artery pressure and pulmonary vascular resistance.
Management of PH involves a multipronged approach, including general measures, targeted therapies, and in severe cases, lung transplantation. General measures include anticoagulation, diuretics, and oxygen therapy. Targeted therapies aim to reverse the pathophysiological changes in PH, and include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs.
PH is a complex, progressive disorder that requires a comprehensive understanding for effective management. Early recognition, accurate diagnosis, and appropriate treatment strategies can significantly improve patient outcomes. As healthcare professionals, staying informed about the latest advancements in PH is crucial to delivering optimal patient care.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation